Gilead's antiviral drug comes through in hep B; Sanofi and MannKind call it quits;

@FierceBiotech: The scoop on every new drug approved in 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Annapurna adds three new gene therapy programs from Ron Crystal's lab at Weill Cornell. Story | Follow @JohnCFierce

@DamianFierce: I cannot prove that OncoCyte got its name from this generator, but I will take credit anyway. Website | Follow @DamianFierce

> Gilead Sciences' ($GILD) antiviral therapy tenofovir alafenamide measured up to the company's approved Viread in a pair of hepatitis B studies. The treatment is also a major part of Gilead's HIV pipeline. News

> Baxalta ($BXLT) and partner CTI BioPharma ($CTIC) submitted pacritinib, a myelofibrosis treatment, for FDA approval. More

> Sanofi ($SNY) and MannKind ($MNKD) are dissolving their diabetes partnership after the latter's inhalable insulin treatment failed to meet expectations. Story

Medical Device News

@FierceMedDev: NIH backs smartphone-based artificial pancreas trials with almost $13M. More | Follow @FierceMedDev

@EmilyWFierce: Pathway Genomics scores $40M in Series E round for genetic test development. Story | Follow @EmilyWFierce

@VarunSaxena2: ICYMI: Scottish researchers develop ingestible 'pill camera' that images non-visible light to detect cancer. More | Follow @VarunSaxena2

> FDA cracks down on transvaginal mesh devices amid safety concerns. More

> Pathway Genomics scores $40M in Series E round for genetic test development. Article

Pharma News

@FiercePharma: Roche resolves patent war with India's Glenmark over generic Tarceva. More | Follow @FiercePharma

@EricPFierce: 18 months after the #FDA slapped Cadila with a Form 483, it sends a warning letter. News | Follow @EricPFierce

@CarlyHFierce: ICYMI: Shire could nab Baxalta for $32B this week: Bloomberg. Story | Follow @CarlyHFierce

> Teva and Takeda fill in details on new Japan generics JV. More

> Lilly falls short of analyst forecasts with 2016 guidance on the 'weaker end.' Article

Pharma Manufacturing News

> Cadila to buy Zoetis animal drugs and feed plant in India for $29M. Item

> FDA slaps two Cadila facilities with warning letters. More

> Orchid gets favorable report for its formulation facility near Chennai. Story

> Reuters: J&J shopping its Noramco API unit for up to $800M deal. News

> FDA unveils new pharma manufacturing program as part of draft guidance. More

Drug Delivery News

> Clearside announces positive Phase II results in win for back-of-the-eye drug delivery. Story

> Halozyme picks up $150M credit deal on its Roche, Baxalta royalties. More

> Amgen partners with Unilife on wearable injectors, may buy 20% stake in the struggling company. Article

> UCSB team makes toxic transdermal drugs safer with salt formulation. News

> FDA approves nonalcoholic formulation of cancer drug, eliminating risk of intoxication following treatment. More

Pharma Asia News

> Japan's push on innovative drugs gets a budget boost. More

> India's hep C market sets a global pace on cost, access. Report

> Indonesia pharma investment cap eyed as top firms plan new plants. Story

> Sinovac gets China FDA new drug, production nod for HFMD vaccine. Article

> EU and India set Jan. 18 date for talks on GVK drug ban. Item

Suggested Articles

Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.

The suit alleges the FDA imposed the hold “without notice or explanation” and has since “rebuffed” Regenxbio’s repeated requests for an explanation.

Bolt Biotherapeutics presented positive results from animal trials of its lead drug, a tumor-targeting antibody connected to an immune stimulator.